O-1821 is primarily used in scientific research to study cannabinoid receptors and their interactions within the body. It acts as a selective agonist for the CB2 receptor, making it a valuable tool for understanding the role of CB2 in immune system regulation, inflammation, and pain management. Researchers utilize O-1821 to explore potential therapeutic applications, particularly in conditions like chronic pain, autoimmune diseases, and neurodegenerative disorders. Its specificity for CB2 receptors allows for targeted studies without significant interference from CB1 receptor activity, providing clearer insights into CB2-mediated pathways. This compound is also employed in preclinical studies to develop and test new cannabinoid-based drugs.